Steven E. Nissen (born 1948) is an American cardiologist, researcher and patient advocate. He was chairman of cardiovascular medicine at the Cleveland Clinic, in Cleveland, Ohio.[1] (wikipedia)
It's really the next generation. It ought to be a magic bullet.
This may be the beginning of a real revolution in the treatment of heart disease. We're not merely slowing down the inexorable progression but truly reversing the disease. It's very exciting.
We've been misled many times by observational studies like this,
I want to cause people's hands to tremble a little bit before they write that (prescription). The only way I know how to do that is to put it in a black box.
I do not think it's wise to approve the drug or see the drug marketed until there's a dedicated cardiovascular safety trial,
I'm not a crusader, I just want the balance between safety and efficacy to be favorable.
We've desperately needed this. The entire public confidence in terms of what is safe for pain has been eroded.
We can't just discuss future strategies, we need to discuss what needs to be done now about the risks and informing people about them. I think a black box is in order that could be removed if information is obtained that does not implicate the drugs.
It could be that we've gotten LDL down as low as we can.
There's only one way -- through good science. We know the burden is upon us to do this right.